Capstone Investment Advisors
APLS

Capstone Investment Advisors’s Apellis Pharmaceuticals APLS Stock Holding History

Capstone Investment Advisors’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-30,500
Closed -$1.31M – 1707
2021
Q1 		$1.31M Hold
30,500
– – ﹤0.01% 1043
2020
Q4 		$1.75M Buy
+30,500
New +$1.29M 0.01% 919

Other funds holding APLS

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Capstone Investment Advisors's APLS Position: Q2 2026 in Review

Capstone Investment Advisors sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 250,000 shares — an estimated $10.1M sold.

Capstone Investment Advisors first reported a position in APLS in Q2 2025 and held it in 3 quarters. The position peaked at $10.1M in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

  • Capstone Investment Advisors reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Capstone Investment Advisors sold 250,000 Apellis Pharmaceuticals shares in Q2 2026, an estimated $10.1M.
  • Capstone Investment Advisors first reported a position in Apellis Pharmaceuticals in Q2 2025 and held it in 3 quarters.
  • Capstone Investment Advisors's Apellis Pharmaceuticals position peaked at $10.1M in Q1 2026.
  • 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on Capstone Investment Advisors's 13F filing for Q2 2026, filed 17 Aug 2026.